Avicanna Inc. (TSX:AVCN) Announces Board Member Resignation

TORONTO, Ontario — May 2, 2026 — Leads & Copy —

Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) has announced the resignation of Eileen McCormack from its board of directors, effective Friday, May 1, 2026. McCormack was not on the slate of directors for re-election or election at the upcoming annual general and special meeting of shareholders scheduled for Thursday May 7, 2026.

Avicanna is a biopharmaceutical company focused on developing, manufacturing, and commercializing plant-derived cannabinoid-based products. The company serves the global medical and pharmaceutical market segments.

Avicanna has established scientific and medical affairs platforms that support its four commercial stage business pillars. These platforms have led to the commercialization of more than fifty finished products.

The company’s Medical Cannabis formulary (RHO Phyto™) offers a range of proprietary products, including oral, sublingual, topical, and transdermal deliveries with varying cannabinoid ratios. The products are supported by patient and medical community education. RHO Phyto™ is available across Canada and is expanding into new international markets.

MyMedi.ca, Avicanna’s medical cannabis care platform, aims to serve medical cannabis patients’ needs and enhance their journey. Operated by Northern Green Canada Inc., MyMedi.ca features a product portfolio and bilingual pharmacist-led patient support programs. It provides specialty services to patient groups, such as veterans, and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca also provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.

Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates in various stages of clinical development. These candidates aim to address unmet needs in dermatology, chronic pain, and various neurological disorders.

The company, through its majority-owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”), supplies active pharmaceutical ingredients. SMGH provides various forms of high-quality CBD, THC, and CBG to the company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of Avicanna’s supply chain and is a source of input products for its consumer retail, medical cannabis, and pharmaceutical products globally.

Source: Avicanna Inc.

×

Welcome!

CannabisReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy

By Subscribing you will receive Daily Cannabis Story Leads via email 10:30 am ET Mon-Fri.